Thesis
PEMGARDA's EUA clock is ticking; everything pivots on whether DECLARATION Phase 3 data earns VYD2311 a BLA before the approved product loses its authorization
Invivyd built its commercial base on PEMGARDA, a neutralizing antibody approved under EUA for COVID-19 prophylaxis in immunocompromised patients, but FDA's termination notice sets a June 2027 expiry on that authorization. The entire forward case rests on DECLARATION Phase 3 top-line data confirming efficacy for VYD2311, enabling a BLA before PEMGARDA revenue evaporates. The approval path itself carries novel risk: the pivotal trial uses a single placebo-controlled study with a 12-week primary endpoint, and any signal of insufficient event accumulation or missed endpoint leaves the company without an approved product and a pipeline of pre-IND assets.
Focus
PEMGARDA EUA termination forces BLA-or-exit decision for primary revenue product
Q3 2026
Bull
Invivyd asserts it has sufficient clinical and post-authorization data to support a BLA submission for PEMGARDA, and FDA Fast Track designation for VYD2311 demonstrates regulatory goodwill toward the company's COVID-19 franchise. If FDA grants an expedited BLA review for PEMGARDA and approves it ahead of the June 2027 deadline, revenue continuity is preserved and the approved product provides a commercial bridge to VYD2311 launch.
Bear
FDA's bar for traditional BLA approval is substantially higher than EUA authorization, and immunocompromised prophylaxis without a randomized placebo-controlled efficacy trial may be insufficient to meet full approval standards, forcing PEMGARDA off market in June 2027. Loss of PEMGARDA revenue before VYD2311 is approved would compress Invivyd's cash runway significantly, particularly given the ATM offering signals ongoing burn pressure.
Unlock the full thesis for IVVD.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.